Cullen Frost Bankers Inc. Buys New Stake in Altimmune, Inc. (NASDAQ:ALT)

Cullen Frost Bankers Inc. bought a new stake in Altimmune, Inc. (NASDAQ:ALT) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 10,000 shares of the company’s stock, valued at approximately $72,000.

A number of other hedge funds have also recently modified their holdings of ALT. Bellevue Group AG grew its position in shares of Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after buying an additional 263,660 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Altimmune in the 3rd quarter valued at $674,000. Barclays PLC grew its position in shares of Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the last quarter. Finally, FMR LLC grew its position in shares of Altimmune by 546.8% in the 3rd quarter. FMR LLC now owns 51,060 shares of the company’s stock valued at $314,000 after buying an additional 43,166 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on ALT. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Monday, March 3rd. UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. William Blair started coverage on shares of Altimmune in a research report on Friday, February 28th. They set a “market perform” rating on the stock. Finally, Stifel Nicolaus started coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Stock Performance

ALT stock opened at $5.57 on Monday. Altimmune, Inc. has a one year low of $5.28 and a one year high of $11.50. The stock has a market capitalization of $428.97 million, a PE ratio of -3.59 and a beta of 0.87. The company has a fifty day moving average of $6.65 and a 200-day moving average of $7.16.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Equities analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.